Skip to main content

Atypical Anti-Psychotic Drugs

Volume 329: debated on Thursday 22 April 1999

The text on this page has been created from Hansard archive content, it may contain typographical errors.

To ask the Secretary of State for Wales what assessment he has made of the efficacy of new atypical anti-psychotic drugs in the treatment of mental health. [81382]

All products that have been licensed will have had their efficacy assessed by the Medicines Control Agency.

To ask the Secretary of State for Wales if he will meet mental health groups to discuss the prescribing of atypical anti-psychotic drugs for mental health patients. [81381]

I am always willing to consider specific requests for meetings with mental health groups.Following the transfer of functions, this issue will be a matter for the National Assembly.

To ask the Secretary of State for Wales what advice he has given to health authorities regarding the prescribing of atypical anti-psychotic drugs for mental health patients. [81380]

WHIN No. (98)13 issued on 1 December 1998 and WHN No. (99)1 issued on 7 January 1999 both related to the withdrawal of the product Serdolect (sertindole). I shall place a copy of these notices in the Library of the House as soon as possible.